TD Cowen analyst Dan Brennan raised the firm’s price target on 10x Genomics to $70 from $66 and keeps an Outperform rating on the shares. The firm said they delivered a solid 2Q beat driven by the Spatial franchise and management raised the guidance at the midpoint which looks conservative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- 10x Genomics price target raised to $75 from $65 at Citi
- 10x Genomics raises 2023 revenue view to $600M-$630M from $590M-$610M
- 10x Genomics reports Q2 EPS (53c), consensus (40c)
- 10x Genomics Reports Second Quarter 2023 Financial Results
- Court permits NanoString counterclaim in 10x Genomics, Harvard litigation